Loading...
XNAS
VANI
Market cap79mUSD
Dec 02, Last price  
1.34USD
1D
0.75%
1Q
15.52%
IPO
-67.63%
Name

Vivani Medical Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
62.16%
Rev. gr., 5y
-14.98%
Revenues
0k
1,367,2241,564,9333,397,8528,950,0003,985,0007,964,0006,896,0003,379,00000000
Net income
-23m
L-8.44%
-16,279,127-22,968,925-35,201,247-20,018,000-33,179,000-28,516,000-35,094,000-33,592,000-9,279,000-12,132,000-6,537,000-25,652,000-23,486,000
CFO
-21m
L-12.29%
-15,321,214-17,426,862-17,092,342-20,549,000-25,070,000-23,947,000-29,810,000-27,629,000-7,619,000-10,950,000-18,787,000-23,699,000-20,786,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
IPO date
Nov 19, 2014
Employees
50
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT